Oppenheimer lowered the firm’s price target on Nyxoah to $15 from $20 and keeps an Outperform rating on the shares. The firm notes Nyxoah reported Q1 revenue in line with its/consensus estimates. DREAM is still on track for FDA approval late 2024/early 2025, with the fourth/final module submission expected Q2 2024, Oppenheimer adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NYXH:
- Nyxoah Excels in Q1 2024, Eyes FDA Approval
- Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024
- Nyxoah Sa (NYXH) Q1 Earnings Cheat Sheet
- Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 12, 2024
- Nyxoah SA Welcomes New Chief Medical Officer